Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

New England Journal of Medicine

Volumn 372, Issue 8, 2014, Pages 724-734

  Swain, Sandra M ^a   Baselga, José ^b   Kim, Sung Bae ^c   Ro, Jungsil ^d   Semiglazov, Vladimir ^e   Campone, Mario ^f   Ciruelos, Eva ^h   Ferrero, Jean Marc ^g   Schneeweiss, Andreas ^j   Heeson, Sarah ^k   Clark, Emma ^k   Ross, Graham ^k   Benyunes, Mark C ^l   Cortés, Javier ⁱ  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c University of Ulsan College of Medicine   (South Korea)

^d National Cancer Center   (South Korea)

^e N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k ROCHE PRODUCTS LTD   (United Kingdom)

^l GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

AGED; ALOPECIA; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADULT; BREAST NEOPLASMS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM METASTASIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84923052492     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1413513     Document Type: Article

References (26)

1. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
2. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
3. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6.
4. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
5. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
6. Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, doubleblind, placebo-controlled phase III study. Oncologist 2013;18:257-64.
7. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001;344:783-92.
10. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-74.
11. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011;29:264-71.
12. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011;29:149-56.
13. Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 2014;25:592-8.
14. Cortés J, Baselga J, Im YH, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013;24:2630-5.
15. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44.
16. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-600.
17. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
18. Amiri-Kordestani L, Wedam S, Zhang L, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014;20:5359-64.
19. Schneeweiss A, Chia S, Hegg R, et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res 2014;16:R73.
20. Gianni L, Bianchini G, Kiermaier A, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized Phase II study ('Neo-Sphere') in patients (pts) with HER2-positive breast cancer (BC). Presented at the 34th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011. abstract.
21. Baselga J, Cortés J, Im S-A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014;32:3753-61.
22. Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2014 December 29 (Epub ahead of print).
23. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
24. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012;30:2585-92.
25. Murthy RK, Varma A, Mishra P, et al. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 2014;120:1932-8.
26. Negri E, Zambelli A, Franchi M, et al. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. Oncologist 2014;19:1209-15.